Contact this trialFirst, we need to learn more about you.
Immunomodulatory agents
Daratumumab vs Lenalidomide for Multiple Myeloma
Recruiting1 awardPhase 2
Middletown, New Jersey
This trial will compare the quality of life for patients with newly diagnosed MM who respond well to initial treatment, between those who receive the standard maintenance therapy (lenalidomide) and those who receive daratumumab as maintenance therapy.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.